Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 27, 2023 10:39am

135 Views

Post# 35559483

RE:RE:RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

"The American Pharmacy Cooperative approved of the FTC's move, saying it had long advocated for federal oversight of PBMs."

[ All positive for the distribution and dispension of ONCY's pelareorep also because Big Pharma's acquisition of ONCY and pelareorep would not be considered as anticompetitive as is the FTC's view of the Amgen / Horizon US$27 Billion merger and very likely any plans for Pfizer to acquire Seagen for US$43 Billion acquisition. ]

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali